Prime Highlights :
- Fresenius launches a €200 million fund to back healthcare startups in biopharma, medtech, and care provision.
- Thomas Michael Thestrup leads the unit, bringing venture experience from Angelini Ventures, Lundbeck, and UCB.
Key Facts :
- Fund targets startups in therapeutics, microbiome research, precision nutrition, and digital care.
- Fresenius Kabi biopharma revenue jumps 43% to €871 million, led by biosimilar Tyenne.
Background :
German healthcare group Fresenius has launched a corporate venture capital unit that plans to invest more than €200 million in healthcare startups over the next five years.
The fund adds fresh strategic capital to a challenging European healthcare financing market. Beyond funding, Fresenius will offer portfolio companies medical, regulatory, and operational expertise, along with access to its clinical, scientific, and academic networks.
The move signals the company’s push to engage with emerging technologies earlier, opening potential paths to partnerships, licensing deals and acquisitions with young biotech firms.
The fund will invest across stages, from early financing rounds through growth stage, targeting areas connected to Fresenius’ three strategic platforms of biopharma, medtech, and care provision.
Potential investment areas include new therapeutic modalities, microbiome research, precision nutrition, and digital care solutions. Fresenius has not disclosed expected ticket sizes, geographic limits, or how capital will be split across sectors.
Thomas Michael Thestrup will lead the new unit. He joins from Angelini Ventures, the corporate venture arm of Italy’s Angelini Industries, bringing prior experience in business development and strategy at Lundbeck and UCB, along with life sciences investing at Danish venture firm Sunstone Capital.
Fresenius has grown from a German pharmacy business into a healthcare group employing more than 178,000 people, generating €22.9 billion in reported revenue.
Its operations center around Fresenius Helios, which runs hospitals in Germany and Spain, and Fresenius Kabi, which sells injectable generic medicines, clinical nutrition products, medical devices, and biopharmaceuticals.
This marks Fresenius’ first dedicated, groupwide corporate venture fund, though the company has made prior moves into biotechnology, including acquiring a biosimilars pipeline, forming a cell and gene therapy joint venture, and taking a majority stake in a Spanish biosimilars manufacturer.
